Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (121-130 of 221) with videos related to

Pageof 23
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 30, 2002
Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin DPeter R Holt, Nadir Arber, Balazs Halmos, et al.
The Oncologist|August 27, 2015
Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung CancerBalazs Halmos, Nathan A Pennell, Pingfu Fu, et al.
Future Oncology (London, England)|August 29, 2020
Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: final analysis of the GioTag studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.
Cancer Research|June 19, 2004
A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancerBalazs Halmos, Daniela S Bassères, Stefano Monti, et al.
Lung Cancer (Amsterdam, Netherlands)|February 9, 2025
Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smokingJoshua E Reuss, Jacob Zaemes, Nishant Gandhi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2Lyudmila Bazhenova, Nofisat Ismaila, Fawzi Abu Rous, et al.
Clinical Lung Cancer|June 26, 2018
Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved CommunityChristopher T Su, Amit Bhargava, Chirag D Shah, et al.
American Journal of Clinical Oncology|January 22, 2019
Impact of Primary Care Access on Mortality of Lung Cancer Patients in an Underserved CommunityChristopher T Su, Vincent Chau, Balazs Halmos, et al.
Cancers|August 29, 2024
Aurora Kinase A Inhibition Potentiates Platinum and Radiation Cytotoxicity in Non-Small-Cell Lung Cancer Cells and Induces Expression of Alternative Immune CheckpointsHuijie Liu, Ayse Ece Cali Daylan, Jihua Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2025
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1Dwight H Owen, Balazs Halmos, Sonam Puri, et al.
Pageof 23

Showing results (121-130 of 221) with videos related to

Sort By:
Pageof 23
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 30, 2002
Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin DPeter R Holt, Nadir Arber, Balazs Halmos, et al.
The Oncologist|August 27, 2015
Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung CancerBalazs Halmos, Nathan A Pennell, Pingfu Fu, et al.
Future Oncology (London, England)|August 29, 2020
Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: final analysis of the GioTag studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.
Cancer Research|June 19, 2004
A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancerBalazs Halmos, Daniela S Bassères, Stefano Monti, et al.
Lung Cancer (Amsterdam, Netherlands)|February 9, 2025
Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smokingJoshua E Reuss, Jacob Zaemes, Nishant Gandhi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2Lyudmila Bazhenova, Nofisat Ismaila, Fawzi Abu Rous, et al.
Clinical Lung Cancer|June 26, 2018
Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved CommunityChristopher T Su, Amit Bhargava, Chirag D Shah, et al.
American Journal of Clinical Oncology|January 22, 2019
Impact of Primary Care Access on Mortality of Lung Cancer Patients in an Underserved CommunityChristopher T Su, Vincent Chau, Balazs Halmos, et al.
Cancers|August 29, 2024
Aurora Kinase A Inhibition Potentiates Platinum and Radiation Cytotoxicity in Non-Small-Cell Lung Cancer Cells and Induces Expression of Alternative Immune CheckpointsHuijie Liu, Ayse Ece Cali Daylan, Jihua Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2025
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1Dwight H Owen, Balazs Halmos, Sonam Puri, et al.
Pageof 23